2009 was the first year that OTC obesity gained a presence in Poland. In April 2009 GlaxoSmithKline Pharmaceuticals SA launched the first orlistat-based OTC obesity product under the Alli brand name. 2009 value sales reached more than PLN4 million.
The OTC Obesity Products in Poland report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2005-2009, allowing you to identify the sectors driving growth. Forecasts to 2014 illustrate how the market is set to change.
Product coverage:
Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.
Why buy this report? - Get a detailed picture of the Consumer Health industry; - Pinpoint growth sectors and identify factors driving change; - Understand the competitive environment, the market’s major players and leading brands; - Use five-year forecasts to assess how the market is predicted to develop.
